Babu Yarlagadda S 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Feb 23, 2021
Insider Transaction Report
Form 4
Babu Yarlagadda S
VP Drug Discovery
Transactions
- Exercise/Conversion
Common Stock
2021-02-19$4.15/sh+50,000$207,500→ 205,587 total - Tax Payment
Common Stock
2021-02-19$11.53/sh−22,431$258,629→ 183,156 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-19−50,000→ 0 totalExercise: $4.15From: 2012-03-01Exp: 2021-03-01→ Common Stock (50,000 underlying)
Footnotes (1)
- [F1]Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise.